Catalent Expands Partnership with J&J
By Tim Wright, Editor, Contract Pharma | 03.17.21
To significantly increase capacity for sterile manufacturing and packaging of COVID-19 vaccine in Italy.
Under the deal, Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy, including vial-filling, inspection, labeling, and packaging services.
Catalent and Janssen had previously agreed to dedicate an existing vial-filling line at the Anagni facility. As part of this expanded agreement, Catalent will accelerate the qualification and scale-up of an additional high-speed vial-filling line that is expected to be operational in the fourth quarter of 2021, to support the production of the Janssen vaccine through late 2022.
Similarly, Catalent’s Bloomington, IN, facility currently provides manufacturing and packaging services for Janssen’s COVID-19 vaccine supply chain in the U.S.